V
Vibliome Therapeutics
Vibliome Therapeutics is developing a new family of therapeutics for the treatment of cancer, contraception and other indications
About Vibliome Therapeutics
Vibliome is a biotechnology company specializing in the development of novel Type II kinase inhibitors. These inhibitors are designed to target and lock kinase enzymes in an inactive conformation, which is crucial for regulating cell functions such as metabolism, division, activation, growth, and death. Aberrations in these pathways are often linked to cancer and other chronic diseases. Unlike traditional high-throughput screening methods, Vibliome employs an early profiling strategy against a panel of more than 400 kinase targets, creating a unique structure-activity relationship (SAR) database with over 2,000 compounds. This approach allows for the fine-tuning of selectivity and efficacy in drug development. The company is also focused on developing a PLK4 inhibitor to treat cancers with TRIM37 amplifications, particularly breast cancer. Vibliome's clients primarily include pharmaceutical companies and research institutions looking for advanced solutions in cancer treatment and chronic disease management. The company operates in the biotechnology and pharmaceutical markets, generating revenue through licensing agreements, partnerships, and direct sales of its proprietary inhibitors.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2022 | $22M | $88M | Deerfield | ↗ |
| EARLY VCEquity / VC | Feb 2019 | $8M | $32M | Undisclosed | — |
Growth signals
Latest recorded traffic for Vibliome Therapeutics is 160 monthly website visits, down 20% over the last three months. Vibliome Therapeutics's team declined 66.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vibliome Therapeutics in the Bozeman ecosystem
The Vibliome Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Deerfield
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vibliome Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vibliome Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









